Effect of pemetrexed combined with gefitinib in the treatment of EGFR mutation positive advanced non-small-cell lung cancer and its influences on TPX2 and GASP-1
Objective To analyze the effect of pemetrexed combined with gefitinib in the treatment of epidermal growth factor receptor(EGFR)mutation positive advanced non-small-cell lung cancer(NSCLC).Methods A total of 90 patients with EGFR mutation positive advanced NSCLC admitted from April 2019 to April 2022 were selected as the research objects.According to the random number table method,the patients were divided into control group(n=45,gefitinib)and study group(n=45,gefitinib+pemetrexed).The therapeutic effects of the two groups were compared.Results The total effective rate of disease control in the study group was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the EGFR,targeting protein for Xenopus kinesin-like protein 2(TPX2),G protein-coupled receptor associated sorting protein-1(GASP-1),tissue inhibitor of metalloprotease-1(TIMP-1)and matrix metalloproteinase-9(MMP-9)levels in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the CD3+,CD4+and CD4+/CD8+in the study group were higher than those in the control group,and the CD8+was lower than that in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Pemetrexed combined with gefitinib in the treatment of EGFR mutation positive advanced NSCLC patients can enhance the clinical efficacy by improve laboratory indicators and enhance immunity,which is worthy of promotion and application.
gefitinibpemetrexedepidermal growth factor receptornon-small-cell lung cancerimmune function
NETL
NSTL
万方数据
